All Work

Chris Lange

Why Nike Favorability Rebounds After Kaepernick Campaign

Nike faced some tough criticism and reactionary setbacks to its reputation when it announced former quarterback Colin Kaepernick as the face of its new “Just Do It” campaign. However, a new report found that…

Chris Lange · 8 years ago

What Analysts Are Saying About Oracle After Earnings

While Oracle's fiscal first-quarter report was not that great, it wasn’t half bad either. Analysts seemed to take a cue from this and their responses to the report were not uniform, with some taking…

Chris Lange · 8 years ago

Tuesday’s Biggest Winners and Losers in the S&P 500

Tuesday was a positive day for the broad U.S. markets with the S&P 500 within points of its all-time high. Crude oil made a solid recovery the session as well. The S&P 500 sectors…

Chris Lange · 8 years ago

Why Tilray Shares Are Getting Even Higher

Tilray continued its incredible rally with shares up massively on Tuesday after the U.S. Drug Enforcement Administration granted approval for the company to import a cannabinoid study drug for a clinical trial at the…

Chris Lange · 8 years ago

Why FedEx Failed to Deliver in Q1

FedEx shares slipped after it reported mixed fiscal first-quarter financial results after the markets closed on Monday.

Chris Lange · 8 years ago

CRISPR Therapeutics Partners Up to Take on Diabetes

CRISPR Therapeutics shares dipped on Monday after the company announced a collaboration with ViaCyte focused on the discovery, development and commercialization of gene-edited allogeneic stem cell therapies for the treatment of diabetes.

Chris Lange · 8 years ago